Koike Y, et al. - In Japanese patients with type 2 diabetes mellitus (T2DM), researchers confirmed the body weight- and fat mass-lowering effects of canagliflozin (CANA) and the accompanying improvement in insulin resistance. The study sample consisted of 38 patients who received 100-mg CANA once daily for 24 weeks. According to findings, CANA treatment significantly reduced hemoglobin A1c, fasting plasma glucose, and plasma liver enzyme levels, and increased plasma adiponectin levels. Furthermore, there was a significant reduction in body weight, visceral and subcutaneous fat area, fat and lean mass and liver steatosis. The change in plasma adiponectin levels correlated significantly with the changes in body fat mass and visceral fat area. They also noted that glucose infusion rate (GIR) increased from 3.25 ± 1.53 to 4.11 ± 1.30 mg/kg/min.